AirSculpt Technologies, Inc. - Common Stock (AIRS)

Management is betting on GLP-1 patients as lead costs climb and guidance drops.

AirSculpt Technologies (NASDAQ:AIRS) lowered its full-year revenue and profit outlook after third-quarter sales fell 8.7%, as fewer potential patients reached its website and several centers experienced operational problems. The body-contouring company reported revenue of $31.9 million for the quar

Same-center case growth turned positive for second consecutive quarter.

AirSculpt Technologies (NASDAQ:AIRS) is seeing stabilization in its core body-contouring business after several quarters of declines, while expanding services aimed at patients using GLP-1 weight-loss drugs, Chief Executive Officer Yogi Jashnani said at a Canaccord consumer conference. The company

AirSculpt Technologies (NASDAQ:AIRS) reported second-quarter revenue of $42.9 million, down 2.5% from the prior-year period, as the company cited stable revenue trends, positive same-center case growth and continued investment in marketing and expanded procedure offerings. Chief Executive Officer Y

AirSculpt (AIRS) Q4 2025 Earnings Transcript

AirSculpt Technologies (NASDAQ:AIRS) executives said the body contouring company has returned to same-store sales growth after more than two years of declines, while outlining plans to expand services tied to GLP-1 weight-loss drug side effects and eventually resume clinic growth across the U.S. Ch

AirSculpt Technologies (NASDAQ:AIRS) reported first-quarter fiscal 2026 results that management characterized as a “key turning point,” citing stabilized revenue, the first positive same-center sales result in more than two years, and continued debt reduction. Q1 results: flat revenue, positive sam